Initial results from the Southwest Oncology Group (SWOG) phase 3 RxPONDER trial demonstrate that postmenopausal women with a common form of breast cancer may be able to forego chemotherapy — and its potential adverse effects — in favor of standalone hormone therapy.
Ongoing research offers new promise for patients with metastasized, castration-resistant prostate cancer.
Endoscopic submucosal dissection was shown to be highly effective at removing superficial gastric tumors and is a viable option for patients around the globe.
Two recently approved treatments show promise in a new study.
New guidelines on how to treat hereditary breast cancer could be a gamechanger.
The recent FDA approval of the drug Tukysa (tucatinib) for use with the chemotherapeutic agents trastuzumab and capecitabine provides a new treatment option to certain adults with HER2-positive breast cancer.
Study Suggests Connection Between Ovarian Cancer and Fibrosis, Provides Possible Risk Management Option
A recent study in Ottawa poses a connection between ovarian fibrosis and the risk of developing ovarian cancer, and hints at a drug that may decrease that risk.
By scrutinizing breast cancer cell lines, tissue grafts and samples, as well as data from The Cancer Genome Atlas, researchers at The Graduate Center of The City University of New York (CUNY) and Hunter College, along with colleagues at Memorial Sloan Kettering Cancer Center and The...